Tscan Therapeutics Financials
| TCRX Stock | USD 7.32 0.03 0.41% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.02 | 6.5136 |
|
|
The financial analysis of Tscan Therapeutics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Tscan Therapeutics includes many different criteria found on its balance sheet. For example, investors should never minimize Tscan Therapeutics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Tscan Therapeutics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Tscan Therapeutics.
Net Income |
|
With this module, you can analyze Tscan financials for your investing period. You should be able to track the changes in Tscan Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Tscan | Select Account or Indicator |
Understanding current and past Tscan Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Tscan Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Tscan Therapeutics' assets may result in an increase in income on the income statement.
The data published in Tscan Therapeutics' official financial statements usually reflect Tscan Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Tscan Therapeutics. For example, before you start analyzing numbers published by Tscan accountants, it's critical to develop an understanding of what Tscan Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Tscan Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tscan Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Tscan Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tscan Therapeutics. Please utilize our Beneish M Score to check the likelihood of Tscan Therapeutics' management manipulating its earnings.
Tscan Therapeutics Stock Summary
Tscan Therapeutics competes with Apellis Pharmaceuticals, Iteos TherapeuticsInc, Day One, Acumen Pharmaceuticals, and X4 Pharmaceuticals. TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Tscan Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 115 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US89854M1018 |
| CUSIP | 89854M101 |
| Location | Massachusetts; U.S.A |
| Business Address | 830 Winter Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.tscan.com |
| Phone | 857 399 9500 |
| Currency | USD - US Dollar |
You should never invest in Tscan Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Tscan Stock, because this is throwing your money away. Analyzing the key information contained in Tscan Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Tscan Therapeutics Key Financial Ratios
Generally speaking, Tscan Therapeutics' financial ratios allow both analysts and investors to convert raw data from Tscan Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Tscan Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Tscan Therapeutics reports annually and quarterly.| Return On Equity | -0.71 | ||||
| Operating Margin | (2.96) % | ||||
| Price To Sales | 17.64 X |
Tscan Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tscan Therapeutics's current stock value. Our valuation model uses many indicators to compare Tscan Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tscan Therapeutics competition to find correlations between indicators driving Tscan Therapeutics's intrinsic value. More Info.Tscan Therapeutics is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . At this time, Tscan Therapeutics' Return On Equity is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Tscan Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Tscan Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tscan Therapeutics' earnings, one of the primary drivers of an investment's value.Tscan Therapeutics Systematic Risk
Tscan Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tscan Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Tscan Therapeutics correlated with the market. If Beta is less than 0 Tscan Therapeutics generally moves in the opposite direction as compared to the market. If Tscan Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tscan Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tscan Therapeutics is generally in the same direction as the market. If Beta > 1 Tscan Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
About Tscan Therapeutics Financials
What exactly are Tscan Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Tscan Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Tscan Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Tscan Therapeutics investors may use each financial statement separately, they are all related. The changes in Tscan Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Tscan Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Tscan Therapeutics Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Tscan Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Tscan has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Tscan Therapeutics' financials are consistent with your investment objective using the following steps:- Review Tscan Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Tscan Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Tscan Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Tscan Therapeutics' stock is overvalued or undervalued.
Tscan Therapeutics Thematic Clasifications
Tscan Therapeutics is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
| Biotech | View |
Today, most investors in Tscan Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tscan Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Tscan Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Tscan Therapeutics April 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tscan Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tscan Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tscan Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Tscan Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tscan Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.05 | |||
| Information Ratio | 0.1359 | |||
| Maximum Drawdown | 28.23 | |||
| Value At Risk | (6.21) | |||
| Potential Upside | 7.88 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Tscan Stock analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Tscan Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tscan Therapeutics. If investors know Tscan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tscan Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.36) | Revenue Per Share 0.321 | Quarterly Revenue Growth 1.33 | Return On Assets (0.25) | Return On Equity (0.71) |
The market value of Tscan Therapeutics is measured differently than its book value, which is the value of Tscan that is recorded on the company's balance sheet. Investors also form their own opinion of Tscan Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tscan Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tscan Therapeutics' market value can be influenced by many factors that don't directly affect Tscan Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tscan Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tscan Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tscan Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.